Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report sent to investors on Monday. The firm issued a sell rating on the stock.

Separately, Maxim Group lowered shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th.

Moleculin Biotech Trading Down 7.8 %

Moleculin Biotech stock opened at $1.77 on Monday. The firm’s fifty day moving average is $1.65 and its 200 day moving average is $2.21. Moleculin Biotech has a 12-month low of $0.40 and a 12-month high of $10.35.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.